GlassScriptPhysician profile
Ilan Shapira
NPI 1649253675
$475,049.95
in general payments reported to CMS, 2019-2025
34 companies · $7,767 in 2025
The $7,767 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111K · 2020: $17K · 2021: $50K · 2022: $155K · 2023: $120K · 2024: $13K · 2025: $7,767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $114K · Travel and Lodging: $15K · Consulting Fee: $7,338 · Food and Beverage: $5,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $113,754.00 |
| Travel and Lodging | $15,377.78 |
| Consulting Fee | $7,338.00 |
| Food and Beverage | $5,100.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $139,793.16 | 2020-2023 | Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $84,334.20 | 2019-2025 | Reblozyl |
| Janssen Biotech, INC. | $83,108.50 | 2019-2025 | Imbruvica, Darzalex, Tecvayli |
| Genentech USA, INC. | $63,432.22 | 2019-2023 | Polivy, Columvi |
| Takeda Pharmaceuticals U.S.A., INC. | $34,001.05 | 2019-2025 | Ninlaro |
| Celgene Corporation | $33,441.22 | 2019-2025 | Reblozyl, Pomalyst |
| Kyowa Kirin, INC. | $8,134.26 | 2019 | |
| Rigel Pharmaceuticals, INC. | $7,847.31 | 2019-2023 | Tavalisse, Rezlidhia |
| Alexion Pharmaceuticals, INC. | $6,773.37 | 2019-2025 | Ultomiris |
| Kite Pharma, INC. | $4,805.88 | 2020 | |
| Stemline Therapeutics INC. | $3,269.37 | 2022-2025 | Elzonris |
| Karyopharm Therapeutics INC. | $2,936.44 | 2024-2025 | Xpovio |
| Beigene USA, INC. | $525.00 | 2022 | |
| Beigene, LTD. | $450.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $400.00 | 2024 | Imfinzi |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $373.94 | 2019-2025 | Epkinly |
| Incyte Corporation | $299.83 | 2021-2025 | Monjuvi |
| Novartis Pharmaceuticals Corporation | $259.46 | 2022-2025 | |
| Amgen INC. | $212.70 | 2019-2022 | |
| Seagen INC. | $132.74 | 2022 | |
| Pharmacosmos Therapeutics INC. | $124.98 | 2021 | |
| Aurobindo Pharma USA, INC. | $115.00 | 2020 | |
| Daiichi Sankyo INC. | $64.73 | 2021-2025 | Enhertu |
| Sobi, INC | $39.80 | 2022-2024 | |
| Glaxosmithkline, LLC. | $38.07 | 2025 | Ojjaara |
| Genmab U.S., INC. | $25.46 | 2023 | Epkinly |
| Morphosys, US INC. | $24.93 | 2021 | |
| Myovant Sciences INC. | $22.46 | 2021 | |
| Genzyme Corporation | $22.18 | 2024 | |
| Tersera Therapeutics LLC | $21.82 | 2025 | Zoladex |
| Acrotech Biopharma INC. | $11.97 | 2021 | |
| Pfizer INC. | $7.90 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilan Shapira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.